PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction
Status:
Completed
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
Obesity and its adverse cardiometabolic consequences are major public health problems.
Several features of obesity contribute to the associated cardiovascular risk and are
potential targets for intervention. These include insulin resistance and beta cell
dysfunction, reduced metabolic rate, and impaired aerobic capacity.The purpose of this study
is to examine if the phosphodiesterase type 5A inhibitor tadalafil improves cardiometabolic
health in individuals who are obese and insulin resistant.
Phase:
Phase 2
Details
Lead Sponsor:
Vanderbilt University Vanderbilt University Medical Center